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Highly Sensitive Method for Genomewide Detection of Allelic
Composition in Nonpaired, Primary Tumor Specimens by Use
of Affymetrix Single-Nucleotide–Polymorphism Genotyping
Microarrays
Go Yamamoto,* Yasuhito Nannya,* Motohiro Kato, Masashi Sanada, Ross L. Levine,
Norihiko Kawamata, Akira Hangaishi, Mineo Kurokawa, Shigeru Chiba, D. Gary Gilliland,
H. Phillip Koeffler, and Seishi Ogawa
Loss of heterozygosity (LOH), either with or without accompanying copy-number loss, is a cardinal feature of cancer
genomes that is tightly linked to cancer development. However, detection of LOH is frequently hampered by the presence
of normal cell components within tumor specimens and the limitation in availability of constitutive DNA. Here, we
describe a simple but highly sensitive method for genomewide detection of allelic composition, based on the Affymetrix
single-nucleotide–polymorphism genotyping microarray platform, without dependence on the availability of constitutive
DNA. By sensing subtle distortions in allele-specific signals caused by allelic imbalance with the use of anonymous
controls, sensitive detection of LOH is enabled with accurate determination of allele-specific copy numbers, even in the
presence of up to 70%–80% normal cell contamination. The performance of the new algorithm, called “AsCNAR” (allele-
specific copy-number analysis using anonymous references), was demonstrated by detecting the copy-number neutral
LOH, or uniparental disomy (UPD), in a large number of acute leukemia samples. We next applied this technique to
detection of UPD involving the 9p arm in myeloproliferative disorders (MPDs), which is tightly associated with a ho-
mozygous JAK2 mutation. It revealed an unexpectedly high frequency of 9p UPD that otherwise would have been
undetected and also disclosed the existence of multiple subpopulations having distinct 9p UPD within the same MPD
specimen. In conclusion, AsCNAR should substantially improve our ability to dissect the complexity of cancer genomes
and should contribute to our understanding of the genetic basis of human cancers.
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Genomewide detection of loss of heterozygosity (LOH),
as well as copy-number (CN) alterations in cancer ge-
nomes, has drawn recent attention in the field of cancer
genetics,1–3 because LOH has been closely related to the
pathogenesis of cancers, in that it is a common mecha-
nism for inactivation of tumor suppressor genes in Knud-
son’s paradigm.4 Moreover, the recent discovery of the
activating Janus kinase 2 gene (JAK2 [MIM *147796]) mu-
tation that is tightly associated with the common 9p LOH
with neutral CNs, or uniparental disomy (UPD), in mye-
loproliferative disorders (MPDs)5–8 uncovered a new par-
adigm—that a dominant oncogenic mutation may be fur-
ther potentiated by duplication of the mutant allele and/
or exclusion of the wild-type allele—underscoring the im-
portance of simultaneous CN detection with LOH anal-
ysis. On this point, Affymetrix GeneChip SNP-detection
arrays, originally developed for large-scale SNP typing,9
provide a powerful platform for both genomewide LOH
analysis and CN detection.10–12 On this platform, the use
of large numbers of SNP-specific probes showing linear
hybridization kinetics allows not only for high-resolution
LOH analysis at ∼2,500–150,000 heterozygous SNP loci
but also for accurate determination of the CN state at each
LOH region.12–14 Unfortunately, however, the sensitivity of
the currently available algorithm for LOH detection by
use of SNP arrays may be greatly reduced when they are
applied to primary tumor specimens that are frequently
heterogeneous and contain significant normal cell
components.
In this article, we describe a simple but highly sensitive
method to detect allelic dosage (CNs) in primary tumor
specimens on a GeneChip platform, with its validations,
and some interesting applications to the analyses of pri-
mary hematological tumor samples. It does not require
paired constitutive DNA of tumor specimens or a large set
of normal reference samples but uses only a small number
of anonymous controls for accurate determination of al-
lele-specific CN (AsCN) even in the presence of significant
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proportions of normal cell components, thus enabling re-
liable genomewide detection of LOH in a wide variety of
primary cancer specimens.
Material and Methods
Samples and Microarray Analysis
Genomic DNA extracted from a lung cancer cell line (NCI-
H2171) was intentionally mixed with DNA from its paired
lymphoblastoid cell line (LCL) (NCI-BL2171) to generate
a dilution series, in which tumor contents started at 10%
and increased by 10% up to 90%. The ratios of admixture
were validated using measurements of a microsatellite
(D3S1279) within a UPD region on chromosome 3 (data
not shown). The nine mixed samples, together with non-
mixed original DNAs (0% and 100% tumor contents),
were analyzed with GeneChip 50K Xba SNP arrays (Af-
fymetrix). Microarray data corresponding to 5%, 15%,
25%,…, and 95% tumor content were interpolated by lin-
early superposing two adjacent microarray data sets after
adjusting the mean array signals of the two sets. Both cell
lines were obtained from the American Type Culture Col-
lection (ATCC). Genomic DNA was also extracted from 85
primary leukemia samples, including 39 acute myeloid
leukemia (AML [MIM #601626]) samples and 46 acute
lymphoblastic leukemia (ALL) samples, and was subjected
to analysis with 50K Xba SNP arrays. Of the 85 samples,
34 were analyzed with their matched complete-remission
bone marrow samples. DNA from 53 MPD samples—13
polycythemia vera (PV [MIM #263300]), 21 essential
thrombocythemia (ET [MIM #187950]), and 19 idiopathic
myelofibrosis (IMF [MIM #254450])—43 of which had
been studied for JAK2 mutations,8 were also analyzed with
50K Xba SNP arrays. Microarray analyses were performed
according to the manufacturer’s protocol,15 except with
the use of LA Taq (Takara) for adaptor-mediated PCR. Also,
DNA from 96 normal volunteers was used for the analysis.
All clinical specimens were made anonymous and were
incorporated into this study in accordance with the ap-
proval of the institutional review boards of the University
of Tokyo and Harvard Medical School.
AsCN Analyses Using Anonymous Control Samples
(AsCNAR)
SNP typing on the GeneChip platform uses two discrete
sets of SNP-specific probes, which are arbitrarily but con-
sistently named “type A” and “type B” SNPs, at every SNP
locus, each consisting of an equal number of perfectly
matched probes (PMAs or PMBs) and mismatched probes
(MMAs or MMBs). For AsCN analysis, the sums of perfectly
matched probes (PMAs or PMBs) for the ith SNP locus in
the tumor (tum) sample and reference samples (ref1,
ref2,…, refN),
tum tum tum tumS p PM , S p PM A,i A,i B,i B,i
and
refI refI refI refIS p PM , S p PM , (Ip 1,2,3,…,N) , A,i A,i B,i B,i
are compared separately at each SNP locus, according to
the concordance of the SNP calls in the tumor sample
( ) and the SNP calls in a given reference sampletumOi
( ),refIOi
tumSA,irefIR pA,i refISA,i
tum refI(for O p O ),i i
tumSB,irefIR pB,i refISB,i
and the total CN ratio is calculated as follows:
refI tum refIR for O p O p AAA,i i i
refI refI tum refIR p R for O p O p BB (Ip 1,2,3, … ,N) .AB,i B,i i i
1 refI refI tum refI{ (R  R ) for O p O p ABA,i B,i i i2
For CN estimations, however, , , and are biasedrefI refI refIR R RAB,i A,i B,i
by differences in mean array signals and different PCR
conditions between the tumor sample and each reference
sample and need to be compensated for these effects to
obtain their adjusted values , , and , respectivelyrefI refI refIˆ ˆ ˆR R RAB,i A,i B,i
(appendix A).16
These values are next averaged over the references that
have a concordant genotype for each SNP in a given set
of references (K), and we obtain , , and . NoteK K K˜ ˜ ˜R R RAB,i A,i B,i
that and are calculated only for heterozygous SNPsK K˜ ˜R RA,i B,i
in the tumor sample (see appendix A for more details).
A provisional total CN profile is provided byLK
K
˜L p {R } ,K AB,i
and provisional AsCN profiles are obtained by
large K K
˜ ˜L p {max(R ,R )}K A,i B,i
small K K
˜ ˜L p {min(R ,R )} .K A,i B,i
These provisional analyses, however, assume that the tu-
mor genome is diploid and has no gross CN alterations,
when the coefficients are calculated in regressions. In the
next step, the regressions are iteratively performed using
a diploid region that is truly or is expected to be diploid,
to determine the coefficients on the basis of the provi-
sional total CN, and then the CNs are recalculated.
Finally, the optimized set of references is selected that
minimizes the SD of total CN at the diploid region by
stepwise reference selection, as described in appendix A.
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Figure 1. AsCN analysis with or without paired DNA. DNA from a lung cancer cell line (NCI-H2171) was mixed with DNA from an LCL
(NCI-BL2171) established from the same patient at the indicated percentages and was analyzed with GeneChip 50K Xba SNP arrays.
AsCNs, as well as total CNs, were analyzed using either the paired reference sample (NCI-BL2171) (upper panels, A–C) or samples from
unrelated individuals simultaneously processed with the tumor samples (middle and lower panels, D–I). On each panel, the upper two
graphs represent total CNs and their moving averages for the adjacent 10 SNPs, whereas moving averages of AsCNs for the adjacent
10 SNPs are shown below (red and green lines). Green and pink bars in the middle are heterozygous (hetero) calls and discordant SNP
calls between the tumor and its paired reference, respectively. At the bottom of each panel, LOH regions inferred from AsCNAR (orange),
SNP call–based LOH inference of CNAG (blue), dChip (purple), and PLASQ (light green) are depicted. Asterisks (*) indicate the loci at
which total CNs were confirmed by FISH analysis (data not shown). The calibrations of CN graphs are linearly adjusted so that the mean
CNs of null and single alleles should be 0 and 1, respectively.
Allele-specific analysis using a constitutive reference,
refSelf, is provided by
large refSelf refSelf
ˆ ˆ{ }L p max(R ,R )A,i B,i
and
small refSelf refSelf
ˆ ˆ{ }L p min(R ,R ) .A,i B,i
Computational details of AsCNAR are provided in appen-
dix A.
Comparison with Other Algorithms
dChip17 and PLASQ18 were downloaded from their sites,
and the identical microarray data were analyzed using
these programs. Since PLASQ requires both Xba and Hind
array data, microarray data of mixed tumor contents for
Hind arrays were simulated by linearly superimposing the
tumor cell line (NCI-H2171) and LCL (NCI-BL2171) data
at indicated proportions.
Statistical Analysis
Significance of the presence of allelic imbalance (AI) in a
given region, G, called as having AI by the hidden Markov
model (HMM), was statistically tested by calculating t sta-
tistics for the difference in AsCNs, , be-K K˜ ˜F log R  log R F2 A,i 2 B,i
tween G and a normal diploid region, where the tests were
unilateral. Significance between the numbers of UPDs de-
tected by the SNP call–based method and by AsCNAR was
tested by one-tailed binominal tests. P values for AI de-
tection by allele-specific PCR were calculated by one-tailed
t tests, comparing triplicates of the target sample and trip-
licates of five normal samples that have heterozygous al-
leles in the SNP.
Detection of the JAK2 Mutation and Measurements
of Relative Allele Doses
The JAK2 V617F mutation was examined by a restriction
enzyme–based analysis, in which PCR-amplified JAK2
exon 12 fragments were digested with BsaXI, and the pres-
ence of the undigested fragment was examined by gel elec-
trophoresis.5 Relative allele dose between wild-type and
mutated JAK2 was determined by measuring allele-specific
PCR products for wild-type and mutated JAK2 alleles by
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Figure 2. Sensitivity and specificity of LOH detection for intentionally mixed tumor samples. Sensitivity of detection of LOH with or
without CN loss (A and B) in different algorithms were compared using a mixture of the tumor sample (NCI-H2171) and the paired LCL
sample (NCI-BL2171). The results for all LOH regions are shown in panel C, and the specificities of LOH detection are depicted in panel
D. For precise estimation of sensitivity and specificity, we defined the SNPs truly positive and negative for LOH as follows. The tumor
sample and the paired LCL sample were genotyped on the array three times independently, and we considered only SNPs that showed
the identical genotype in the three experiments. SNPs that were heterozygous in the paired LCL sample and were homozygous in the
tumor sample were considered to be truly positive for LOH, and SNPs that were heterozygous both in the paired LCL sample and in the
tumor sample were considered to be truly negative. Proportions of heterozygous SNP calls (%hetero-call) that remained in LOH regions
of each sample are also shown in panels A–C.
capillary electrophoresis by use of the 3100 Genetic An-
alyzer (Applied Biosystems), as described in the litera-
ture.19 Likewise, the fraction of tumor components having
9p and other UPDs was measured by either allele-specific
PCR or STR PCR,7,19 by use of the primers provided in
appendix B [online only]. The percentage of UPD-positive
cells (%UPD()) was also estimated as the mean difference
of AsCNs for heterozygous SNPs within the UPD region
divided by that for homozygous SNPs within an arbitrary
selected normal region:
K K
˜ ˜E(FR R F )A,i B,i ihetero SNPs in UPD region%UPD()p ,K K
˜ ˜E(FR R F )A,j B,j jhomo SNPs with normal CN
where AsCNs for the denominator were calculated as if
the homozygous SNPs were heterozygous. However, in
those samples with a high percentage of UPD-positive
components, the heterozygous SNP rate in the UPD region
decreased. For such regions, we calculated the percentage
of UPD-positive cells by randomly selecting 30% (the
mean heterozygous SNP call rate for this array) of all the
SNPs therein and by assuming that they were heterozy-
gous SNPs. Cellular composition of JAK2 wild-type (wt)
and mutant (mt) homozygotes (wt/wt and mt/mt) and
heterozygotes (wt/mt) in each MPD specimen was esti-
mated assuming that all UPD components are homozy-
gous for the JAK2 mutation. The fractions of the wt/mt
heterozygotes in cases with a 9p gain were estimated as-
suming that the duplicated 9p alleles had the JAK2 mu-
tation. Throughout the calculations, small negative values
for wt/mt were disregarded.
FISH
FISH analysis was performed according to the previously
published method, to confirm the absolute total CNs in
NCI-H2171.20 The genomic probes were generated by
whole-genome amplification of FISH-confirmed RP11 BAC
clones 169N13 (3q13; ), 227F7 (8q24; ),CNp 2 CNp 2
196H14 (12q14; ), 25E13 (13q33; ), 84E24CNp 2 CNp 2
(17q24; ), 12C9 (19q13; ), 153K19 (3q13;CNp 2 CNp 2
), 94D19 (3p14; ), 80P10 (8q22; ),CNp 3 CNp 1 CNp 1
and 64C21 (13q12-13; ), which were obtainedCNp 1
from the BACPAC Resources Center at the Children’s Hos-
pital Oakland Research Institute in Oakland, California.
Results
SNP Call–Based Genomewide LOH Detection by Use of SNP
Arrays
When a pure tumor sample is analyzed with a paired con-
stitutive reference on a GeneChip Xba 50K array, LOH is
easily detected as homozygous SNP loci in the tumor spec-
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Figure 3. The number of UPD regions for acute leukemia and
MPD samples detected by either the SNP call–based method or
AsCNAR. The number of UPD regions for ALL and AML samples
detected by the SNP call–based method or by AsCNAR is shown in
panel A, and the number of 9p UPDs for MPD samples detected
by the two methods is shown in panel B. Some samples have more
than one UPD region. Details of UPD regions are given in table 1.
Significance between the numbers of UPDs detected by the SNP
call–based method and by the AsCNAR method was tested by one-
tailed binomial tests.
Table 1. CN-Neutral LOH in Primary Acute
Leukemia
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
imen that are heterozygous in the constitutive DNA (fig.
1A, pink bars). In addition, given a large number of SNPs
to be genotyped, the presence of LOH is also inferred from
the grossly decreased heterozygous SNP calls, even in the
absence of a paired reference (fig. 1D). The accuracy of the
LOH inference would depend partly on the algorithm used
but more strongly on the tumor content of the specimens.
Thus, our SNP call–based LOH inference algorithm in
CNAG (appendix C), as well as that of dChip,17 show al-
most 100% sensitivity and specificity for pure tumor spec-
imens. But, as the tumor content decreases, the LOH de-
tection rate steeply declines (fig. 1G), and, with !50%
tumor cells, no LOH can be detected, even when complete
genotype information for both tumor and paired consti-
tutive DNA is obtained (fig. 1B, 1E, 1H, and 1I).
LOH Detection Based on AsCN Analysis
On the other hand, the capability of allele-specific mea-
surements of CN alterations in cancer genomes is an ex-
cellent feature of the SNP array-based CN-detection system
that uses a large number of SNP-specific probe sets.16,18,21
When constitutive DNA is used as a reference, AsCN anal-
ysis is accomplished by separately comparing the SNP-
specific array signals from the two parental alleles at the
heterozygous SNP loci in the constitutive genomic DNA.16
It determines not only the total CN changes but also the
alterations of allelic compositions in cancer genomes,
which are captured as the split lines in the two AsCN
graphs (fig. 1A and 1B). In this mode of analysis, the pres-
ence of LOH can be detected as loss of one parental allele,
even in specimens showing almost no discordant calls (fig.
1B).
AsCNAR
The previous method for AsCN analysis, however, essen-
tially depends on the availability of constitutive DNA,
since AsCNs are calculated only at the heterozygous SNP
loci in constitutive DNA.16 Alternatively, allele-specific sig-
nals can be compared with those in anonymous references
on the basis of the heterozygous SNP calls in the tumor
specimen. In the latter case, the concordance of hetero-
zygous SNP calls between the tumor and the unrelated
sample is expected to be only 37% with a single reference.
However, the use of multiple references overcomes the low
concordance rate with a single reference, and the expected
overall concordance rate for heterozygous SNPs and for
all SNPs increases to 86% and 92%, respectively, with five
unrelated references (appendix D [online only]). Thus, for
AsCNAR, allele-specific signal ratios are calculated at all
the concordant heterozygous SNP loci for individual ref-
erences, and then the signal ratios for the identical SNPs
are averaged across different references over the entire ge-
nome. For the analysis of total CNs, all the concordant
SNPs, both homozygous and heterozygous, are included
in the calculations, and the two allele-specific signal ratios
for heterozygous SNP loci are summed together. Since
AsCNAR computes AsCNs only for heterozygous SNP loci
in tumors, difficulty may arise on analysis of an LOH re-
gion in highly pure tumor samples, in which little or no
heterozygous SNP calls are expected. However, as shown
above, such LOH regions can be easily detected by the
SNP call–based algorithm, where AsCNAR is formally cal-
culated assuming all the SNPs therein are heterozygous.
Thus, the AsCNAR provides an essentially equivalent re-
sult to that from AsCN analysis using constitutional DNA,
with similar sensitivity in detecting AI and LOH (compare
fig. 1A with 1D and 1B with 1E).
As expected from its principle, AsCNAR is more robust
in the presence of normal cell contaminations than are
SNP call–based algorithms. To evaluate this quantitatively,
we analyzed tumor DNA that was intentionally mixed
with its paired normal DNA at varying ratios in 50K Xba
SNP arrays, and the array data were analyzed with
AsCNAR. To preclude subjectivity, LOH regions were de-
tected by an HMM-based algorithm, which evaluates dif-
ference in AsCNs in both parental alleles (appendix E).22
As the tumor content decreases, the SNP call–based LOH
inference fails to detect LOH because of the appearance
of heterozygous SNP calls from the contaminated normal
cell component (fig. 1E and 1G–1I), but these heterozy-
gous SNP calls, in turn, make AsCNAR operate effectively.
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Figure 4. Detection of AI in samples of primary AML and MPD. AsCN analyses disclosed the presence of a small population with 17p
UPD in a primary AML specimen (W150673) (93% blasts in microscopic examination) with either a paired sample (A) or anonymous
reference samples (B). The difference of the mean CNs of the two parental alleles is statistically different between panels A (0.38) and
B (0.55) ( , by t test), which is explained by the residual tumor component within the bone marrow sample in completeP ! .0001
remission (1% blast) used as a paired reference (W150673CR) (C). AI in the 9p arm was also sensitively detected in JAK2 mutation–
positive MPD cases. UPD may be carried only by a very small population (∼20% estimated from the mean deviation of AsCNs in 9p)
(IMF_10) (D), or by two discrete populations within the same case (PV_06), as indicated by two-phased dissociation of AsCN graphs
(pink and green arrows) (F). AI in 9p is mainly caused by UPD but may be caused by gains of one parental allele without loss of the
other allele (E), both of which are not discriminated by conventional allele measurements. Blue and pink bars are UPD and AI calls,
respectively, from the HMM-based LOH detection algorithm. Other features are identical to those indicated in figure 1.
In fact, this algorithm precisely identifies known LOH
regions, as well as regions with AI, in intentionally mixed
tumor samples containing as little as 20% (for LOH with-
out CN loss) to 25% (LOH with CN loss) tumor contents
(fig. 2A–2C). Note that this large gain in sensitivity is ob-
tained without the expense of specificity, which is very
close to 100%, as observed with other algorithms (fig. 2D).
In AsCNAR, small regions of AI (!1 million bases in length)
are difficult to detect in samples contaminated with nor-
mal cells. However, such regions are also difficult to detect
using other algorithms (data not shown).
Identification of UPD in Primary Tumor Samples
To examine further the strength of the newly developed
algorithms for AsCN and LOH detection, we explored UPD
regions in 85 primary acute leukemia samples, including
39 AML and 46 ALL samples, on GeneChip 50K Xba SNP
arrays, since recent reports identified frequent (∼20%) oc-
currence of this abnormality in AML.23,24 In the SNP call–
based LOH inference algorithm, 16 UPD regions were
identified in 14 cases, 8 (20.5%) AML and 6 (13.0%) ALL.
However, the frequencies were almost doubled with the
AsCNAR algorithm; a total of 28 UPD loci were identified
in 25 cases, including 14 (35.9%) AML and 11 (23.9%)
ALL (fig. 3A and table 1). In 5 of the 25 UPD-positive cases,
a matched remission sample was available for AsCN anal-
ysis, which provided essentially the same results as
AsCNAR, except for one relapsed AML case (W150673).
In the latter case, a discrepancy in AsCN shifts in 17p UPD
occurred between AsCN analysis with and without a con-
stitutive reference, with more CN shift detected with
anonymous references (fig. 4A and 4B). The discrepancy
was, however, explained by the unexpected detection of
a subtle UPD change in 17p in the reference sample by
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Table 2. AI of 9p in JAK2 Mutation-Positive MPDs
Case
9p Status by AsCNAR
Detection
by SNP
Call–Based
Methoda
% JAK2
Mutationb
Allele-Specific PCRc
Type Break Pointd %UPDe SNP %UPDf Pg
PV_02 Gain 42.9 99 NA 63 rs2009991 84 .004
PV_03 Gain Whole 60 NA 39 rs10511431 63 .008
PV_04 UPD 37.0 93 D 95 5Homo 5Homo 5Homo
PV_08 UPD 34.2 91 D 93 5Homo 5Homo 5Homo
PV_07 UPD 23.8 88 D 90 5Homo 5Homo 5Homo
PV_06 UPDh 7.1/35.3 83 D 93 5Homo 5Homo 5Homo
PV_11 UPD 31.2 68 D 76 5Homo 5Homo 5Homo
PV_13 UPD 28.1 66 ND 48 rs1416582 64 .001
PV_01 UPD 20.9 56 ND 62 rs10511431 49 .007
PV_09 UPD 30.8 38 ND 30 rs10491558 32 .020
PV_05 UPD 23.5 32 ND 33 rs1374172 31 .010
IMF_04 UPD 33.8 79 D 90 5Homo 5Homo 5Homo
IMF_05 UPD 37.0 58 ND 57 rs1416582 49 .004
IMF_07 UPD 20.3 52 ND 50 rs1416582 57 .005
IMF_12 UPDh 26.8/42.9 52 ND 66 5Homo 5Homo 5Homo
IMF_14 UPDh 22.8/33.8 45 ND 56 rs1374172 35 .015
IMF_19 UPD 34.4 26 ND 43 rs10511431 33 .017
IMF_10 UPD 34.6 21 ND 36 rs1374172 21 .049
IMF_15 UPD 33.8 21 ND 17 rs10511431 20 .084
IMF_06 UPD 35.3 17 ND 28 rs1374172 20 .048
IMF_16 () NA NA NA 37 NA NA NA
ET_12 Gain Whole 42 NA 27 rs2009991 36 .046
ET_14 UPD 42.9 63 ND 45 rs1374172 54 .006
ET_01 UPD 35.4 19 ND 59 rs10511431 33 .017
ET_05 () NA NA NA 23 NA NA NA
ET_08 () NA NA NA 42 NA NA NA
ET_09 () NA NA NA 34 NA NA NA
ET_10 () NA NA NA 16 NA NA NA
ET_15 () NA NA NA 27 NA NA NA
ET_18 () NA NA NA 17 NA NA NA
ET_19 () NA NA NA 27 NA NA NA
ET_21 () NA NA NA 55 NA NA NA
NOTE.—NA p not applied; () p neither UPD nor gain of 9p was detected by AsCNAR analysis.
a D p UPD was detected by SNP call–based method; ND p not detected.
b Percentage of JAK2 mutant alleles, as measured by allele-specific PCR.
c 5Homo p all five tested SNPs were homozygous.
d Position of the break point from the p-telomeric end (values are in Mb). The location of JAK2
corresponds to 5 Mb.
e Percentage of tumor cell populations with either UPD or gain of 9p, as determined by AsCNAR analysis.
f Percentage of tumor cell populations with either UPD or gain of 9p, as determined by the allele-
specific PCR.
g P values were derived from one-tailed t tests comparing triplicate analyses of the target sample and
triplicate analyses of five normal samples.
h Two UPD-positive populations exist.
AsCNAR ( , by t test) (fig. 4C), which offset theP ! .0001
CN shift in the relapsed sample, although it was mor-
phologically and cytogenetically diagnosed as in complete
remission.
Analysis of 9p UPD in MPDs
Another interesting application of the AsCNAR is the anal-
ysis of allelic status in the 9p arm among patients with
MPD, which includes PV, ET, and IMF. According to past
reports, ∼10% (in ET) to ∼40% (in PV) of MPD cases with
the activating JAK2 mutation (V617F) show evidence of
clonal evolution of dominant progeny that carry the ho-
mozygous JAK2 mutation caused by 9p UPD.5,7,8 In our
series that included 53 MPD cases, the JAK2 mutation was
detected in 32 (60%), of which 13 (41%) showed 150%
mutant allele by allele measurement with the use of allele-
specific PCR, and thus were judged to have one or more
populations carrying homozygous JAK2 mutations (table
2). This frequency is comparable to that reported else-
where.8 However, when the same specimens were ana-
lyzed with 50K Xba SNP arrays by use of the AsCNAR
algorithm, 20 of the 32 JAK2 mutation–positive cases were
demonstrated to have minor UPD subpopulations (table
2 and fig. 3B), in which as little as 17% of UPD-positive
populations were sensitively detected (fig. 4D). In fact,
these minor (!50%) UPD-positive populations in these
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Figure 5. Estimation of tumor populations carrying 9p UPD and the JAK2 mutation in MPD samples. The populations of 9p UPD–
positive components in the 53 MPD cases were estimated by calculation of the mean difference of AsCNs within the UPD regions.
Heterozygous (blue bars) or homozygous (red bars) JAK2 mutations in MPD samples were also estimated by measurement of JAK2 mutated
alleles and UPD alleles, under the assumption that all the UPD alleles have a JAK2 mutation. Measurement of JAK2 mutated alleles was
performed by allele-specific PCR. For three cases having trisomy components (orange bars), the duplicated allele was assumed to have
a JAK2 mutation, which is the consistent interpretation of the observed fraction of trisomy and mutated JAK2 alleles for case PV_02
(table 2). mt p JAK2 mutated allele; wt p wild-type allele.
cases were also confirmed by allele-specific PCR of SNPs
on 9p (table 2). The proportion of 9p UPD–positive com-
ponents estimated both from allele-specific PCR and from
AsCNAR (see the “Material and Methods” section) shows
a good concordance (table 2). In some cases, 9p UPD–
positive cells account for almost all the JAK2 mutation–
positive population, whereas, in others, they represent
only a small subpopulation of the entire JAK2 mutation–
positive population (fig. 5). AsCNAR analysis also dis-
closed the additional three cases that have 9p gain (9p
trisomy) (fig. 4E). The 9p trisomy is among the most-fre-
quent cytogenetic abnormalities in MPDs25 and is impli-
cated in duplication of the mutated JAK2 allele6 but could
not have been discriminated from UPD or “LOH with CN
loss” by use of conventional techniques—for example, al-
lele-specific PCR to measure relative allele dose. Since the
proportions of the mutated JAK2 allele coincide with two-
thirds of the observed trisomy components in all three
cases, the data suggest that the mutated JAK2 allele is du-
plicated in the 9p trisomy cases (table 2). Of particular
interest is the unexpected finding of the presence of two
discrete populations carrying 9p UPD in three cases, in
which the AsCN graph showed a two-phased dissociation
along the 9p arm (fig. 4F). In the previous observations,
homozygous JAK2 mutations have been reported to be
more common in PV cases (∼40%) than in ET cases
(!∼10%). With AsCNAR analysis, the difference in the fre-
quency of 9p UPD becomes more conspicuous; nearly all
PV cases (11/11) and IMF cases (9/10) with a JAK2 mu-
tation had one or more UPD components or other gains
of 9p material, whereas only 3 of the 11 JAK2 mutation-
positive ET cases carried a 9p UPD component or gain of
9p ( , by Fisher’s exact test).4Pp 1.3# 10
Discussion
The robustness of the AsCNAR method lies in its capacity
to measure accurately allele dosage and thereby to detect
LOH even in the presence of significant normal cell com-
ponents, which often occurs in primary tumor samples.
In principle, an accurate LOH determination is accom-
plished only by demonstrating an absolute loss of one
parental allele, not simply by detecting AI with conven-
tional allele-measurement techniques. This is especially
the case for contaminated samples, where it is essentially
impossible to discriminate the origin of the remaining
minor-allele component (i.e., differentiating normal cells
and tumor cells).1,3 Nevertheless, and paradoxically, it is
these normal cells within the tumor samples that enable
determination of AsCNs in AsCNAR. It computes AsCNs
on the basis of the strength of heterozygous SNP calls
produced from the “contaminated” normal component,
which effectively works as “an internal reference,” pre-
cluding the need for preparing a paired germline reference.
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Figure 6. Effects of the use of the different reference sets on
signal-to-noise (S/N) ratios in CN analysis. The legend is available
in its entirety in the online edition of The American Journal of
Human Genetics.
Figure 7. CN profile obtained with the use of a varying number
of anonymous references. The legend is available in its entirety
in the online edition of The American Journal of Human Genetics.
It far outperforms the SNP call–based LOH-inference
algorithms and other methods and definitively deter-
mines the state of LOH by sensing CN loss of one parental
allele.
In the previously published algorithms, AsCN analysis
was enabled by fitting observed array data to a model con-
structed from a fixed data set from normal samples.18,21
However, the model that explicitly assumes integer CNs
fails to cope with primary tumor samples that contain
varying degrees of normal cell components (PLASQ)18 (fig.
2). Another algorithm (CARAT) requires a large number
of references to construct a model by which AsCNs are
predicted, but such a model may not necessarily be prop-
erly applied to predict AsCNs for the newly processed sam-
ples, if the experimental condition for those samples is
significantly different from that for the reference samples,
which were used to construct the model (fig. 6 and data
not shown).21 Signal ratios between array data from very
different experiments could be strongly biased, to the ex-
tent that they can no more be properly compensated by
conventional regressions. In contrast, AsCNAR uses just a
small number of references simultaneously processed with
tumor specimens, to minimize difference in experimental
conditions between tumor and references, which act as
excellent controls in calculating AsCNs, although refer-
ences analyzed in short intervals also work satisfactorily
(data not shown).
The CN analysis software for the Illumina array provides
allele frequencies, as well as CNs, by use of a model-based
approach, and, as such, it enables AsCN analysis but seems
to be less sensitive for detection of AIs.26 AsCNAR can be
easily adapted to other Affymetrix arrays, including 10K
and 500K arrays, and may be potentially applied to Illu-
mina arrays.
The probability of finding at least one concordant SNP
between a tumor sample and a set of anonymous refer-
ences is enough with five references, but use of just one
reference provides almost an equivalent AsCN profile to
that obtained with its paired reference (fig. 7). The sen-
sitivity and specificity of LOH detection with this algo-
rithm are excellent, even in the presence of significant
degrees of normal cell components (∼70%–80%), which
circumvent the need for purifying the tumor compo-
nents for analysis—for example, by time-consuming
microdissection.
Because the AsCNAR algorithm is quite simple, it re-
quires much less computing power and time (several sec-
onds per sample on average laptop computers) than do
model-based algorithms. For example, with PLASQ, it
takes overnight for model construction and an additional
hour for processing each sample.
The high sensitivity of LOH detection by AsCNAR has
been validated not only by the analysis of tumor DNA
intentionally mixed with normal DNA but also by the
analysis of primary leukemia samples. It unveiled other-
wise undetected, minor UPD-positive populations within
leukemia samples. Especially, the extremely high fre-
quency of 9p UPD or gains of 9p in particular types of
JAK2 mutation–positive MPDs, as well as multiple UPD-
positive subclones in some cases, demonstrated how
strongly and efficiently a genetic change (point mutation)
works to fix the next alteration (mitotic recombination)
in the tumor population during clonal evolution in hu-
man cancer. Finally, the conspicuous difference in UPD
frequency among different MPD subtypes (PV and IMF vs.
ET) is noteworthy. This is supported by a recent report
that demonstrated the presence of minor subclones car-
rying exclusively the mutated JAK2 allele in all PV sam-
ples, but in none of the ET samples, by examining a large
number of erythroid burst-forming units and Epo-inde-
pendent erythroid colonies for JAK2 mutation.27 Our ob-
servation also supports their hypothesis that the biological
behavior of these prototypic stem-cell disorders with a
continuous disease spectrum could be determined by the
components with either homozygous or duplicated JAK2
mutations.
In conclusion, the AsCNAR with use of high-density
oligonucleotide microarrays is a robust method of ge-
nomewide analysis of allelic changes in cancer genomes
and provides an invaluable clue to the understanding of
the genetic basis of human cancers. The AsCNAR algo-
rithm is freely available on our CNAG Web site for aca-
demic users.
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Appendix A
AsCNAR
Quadratic Regression
The log2 signal-ratio, is regressed by the qua-
refIlog R2 AB,i
dratic terms (the length [ ] and the GC content [ ] ofL Mi i
the PCR fragment of the ith SNP) as
refI 2 2log R p aL  bL  xM  dM  g  ,2 AB,i i i i i i
where is the error term and the coefficients of regressionsi
a, b, x, d, and g are dependent on the reference used and
are determined to minimize the residual sum of squares
(i.e., ). Note that the sum is taken for those SNPs that2 ii
have concordant SNP calls between the tumor and the
reference samples.
We suppose that both allele A DNA and allele B DNA
follow the same PCR kinetics, and allele-specific ratios
and , respectively, can be regressed by the samerefI refIR RA,i B,i
parameters, as
refI refI 2 2
ˆ ( ) ( )log R p log R  aL  bL  xM  dM g2 A,i 2 A,i i i i i
and
refI refI 2 2
ˆ ( ) ( )log R p log R  aL  bL  xM  dM g ,2 B,i 2 B,i i i i i
and the corrected total CN ratio is
refI tum refI
ˆR for O p O p AAA,i i i
refI refI tum refI
ˆ ˆR p R for O p O p BB .AB,i B,i i i
1 refI refI tum refI{ ˆ ˆ( )R R for O p O p ABA,i B,i i i2
Averaging over the References of Concordance SNPs
Concordant reference sets and for each SNPK K,heteroC Ci i
Si for a given set of references, K, are defined as follows:
K tum refI{ }C p refIFO p O ,refI Ki i i
K,hetero tum refI{ }C p refIFO p O p AB,refI K ,i i i
and the averaged CN ratio, , is provided byK˜RAB,i
1K refI K
˜ ˆR p R , C ( fAB,i AB,i iK
K#C refICii
where “#” denotes the number of the elements of the set.
Similarly, AsCN ratios are obtained by
1K refI
˜ ˆR p RA,i A,iK,hetero
K,hetero#C refICii
K,hetero(C ( f) .i
1K refI
˜ ˆR p RB,i B,iK,hetero
K,hetero#C refICii
Exceptional Handling with Regions of Homozygous
Deletion, High Amplification, and LOH
To prevent SNPs within the regions that show homo-
zygous deletion or high-grade amplification from being
analyzed as “homozygous SNPs,” a homozygous SNP
Si in the tumor sample is redefined as a heterozygous
SNP with , if ortum K Kˆ ˜ ˜O p AB max(log R , log R )  0.1i 2 A,i 2 B,i
, where and are cal-K K K K˜ ˜ ˜ ˜min(log R , log R )0.1 R R2 A,i 2 B,i A,i B,i
culated supposing SNP Si is heterozygous. These cutoff val-
ues (0.1 and 0.1) are determined by receiver operating
characteristic (ROC) curve for detection of gain of the
larger allele and loss of the smaller allele in a sample con-
taining 20% tumor cells (data not shown). In addition,
SNPs within inferred LOH regions are also analyzed as
“heterozygous” SNPs.
Reference Selection
The optimized set of references is selected that mini-
mizes the SD of total CN at the diploid region D,
2K
˜( ) log R2 AB,i
KiD,C(f iSD (D)p .K K#{iFiD,C ( f} 1i
To do this, instead of testing all possible 2N combinations
of N references, we calculate for individual refer-SD (D)K
ences to order the ref-Kp {ref1} , {ref2} , {ref3} ,…, {refN} ,
erences such that SD (D)… SD (D) SD (D)…1 s s1
, where 1, 2, 3,…,s, s1,…, N denotes the orderedSD (D)N
references. The optimal set is de-K(N )p {1,2,3,…,N }0 0
termined by choosing N0 that satisfies SD (D)…K(1)
.SD (D) ! SD (D)K(N ) K(N 1)0 0
Note that, in principle, a diploid region cannot be un-
equivocally determined without doing single-cell–based
analysis—for example, FISH or cytogenetics. Otherwise, a
diploid region is empirically determined by setting the
CN-minimal regions with no AI as diploid, which provides
correct estimation of the ploidy in most cases (data not
shown).
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Figure C1. Inference of LOH on the basis of heterozygous SNP
calls. The legend is available in its entirety in the online edition
of The American Journal of Human Genetics.
Figure E1. Sensitivity and specificity for determination of AI,
LOH, and UPD. The legend is available in its entirety in the online
edition of The American Journal of Human Genetics.
Appendix C
Inference of LOH Based on Heterozygous SNP Calls
For a given contiguous region between the ith andQi,j
jth SNPs ( ) and for the complete set of observed SNPi j
calls therein, , consider the log likelihood ratioO(Q )i,j
P(O(Q )FQ  LOH)i,j i,jZ(Q ){ ln ,i,j P(O(Q )FQ  LOH)i,j i,j
where the ratio is taken between the conditional proba-
bilities that the current observation, , is obtainedO(Q )i,j
under the assumption that belongs to LOH or not.O(Q )i,j
We assume a constant miscall rate ( ) for all SNPqp 0.001
and use the conditional probability that the kth SNP is
heterozygous (hk), depending on the observed k1th SNP
call, for partially taking the effect of linkage disequilibrium
into account:
Z(Q )pi,j
 {(1 q)O  q(1O )}k k
ikjln  [{(1 h )(1 q) h q}O  {(1 h )q h (1 q)}(1O )]k k k k k k
ikj
where hk is calculated using the data from the 96 normal
Japanese individuals, whereas Ok takes either 1 or 0, de-
pending on the kth SNP call, with 1 for a homozygous
call and 0 for a heterozygous call. For each chromosome,
a set of regions, ( ), canQ (J ! I  J ,J p 0) np 1,2,3,…I ,J n1 n n 0n n
be uniquely determined as follows.
Beginning with the SNP at the short arm end ( ), findS0
the SNP that satisfies and forS Z(Q ) 1 0 Z(Q )  0I I ,I i,in n n
(fig. C1). Identify the SNP , such thatJ ! Gi ! I S n1 n J
for and , or that isZ(Q ) 1 0 I  Gj J Z(Q ) 0 S I ,j n I ,J 1 Jn n
the end of the chromosome (fig. C1). Then, put asJn
(fig. C1). This procedure isarg max Z(Q )(I  j J )j I ,j nn
iteratively performed, beginning the next iteration
with the SNP , until it reaches to the end of the longSJ 1n
arm, generating a set of nonoverlapping regions,
. LOH inference is now enabled byQ ,Q ,Q ,…Q ,…I ,J I ,J I ,J I ,J1 1 2 2 3 3 n n
testing each against a threshold (25), which is ar-Z(Q )I ,Jn n
bitrarily determined from the ROC curve for LOH deter-
mination on a DNA sample from a lung cancer cell line,
NCI-H2171 (fig. C1). This algorithm is implemented in
our CNAG program, which is available at our Web site.
Appendix E
Algorithm for Detection of AI With or Without LOH
The regions with AI are inferred from the AsCN data by
use of an HMM, where the real state of AI (a hidden state)
is inferred from the observed states of difference in AsCNs
of the two parental alleles, which are expressed as di-
chotomous values (“preset” or “absent”) according to a
threshold ( ). The emission probabilities at the ith SNPm
locus (Si) are
K K
˜ ˜P(F log R  log R F mFSi AI)p b2 A,i 2 B,i
K K
˜ ˜P(F log R  log R F 1 mFSi AI)p 1 b2 A,i 2 B,i
and
—
K K
˜ ˜P(F log R  log R F 1 mFSi AI)p a2 A,i 2 B,i
—
K K
˜ ˜P(F log R  log R F mFSi AI)p 1a2 A,i 2 B,i
(see also the “Material and Methods” section and appen-
dix A for calculation of and ).K K˜ ˜R RA,i B,i
The parameters ( , , and ) are determined by the re-m a b
sults of 10%, 20%, and 30% tumor samples. Sensitivity
and specificity are calculated with varying threshold ( ),m
where sensitivity is defined as the ratio of detected SNPs
of UPD region detected in the 100% tumor sample, spec-
ificity is defined as the ratio of nondetected SNPs in nor-
mal samples, and and parameters are determined froma b
mixed tumor-sample data for each threshold value. Sen-
sitivity and specificity are relatively stable and are within
the acceptable range when the threshold is between 0.05
and 0.15 in 20% and 30% tumor samples (fig. E1). We
used 0.12, 0.17, and 0.06 for , , and , respectively, onm a b
the basis of 20% tumor-sample data.
Considering that UPD is caused by a process similar to
recombination, the Kosambi’s map function (1/2)tanh(2v)
is used for transition probability, where v is the distance
between two SNPs, expressed in cM units; for simplicity,
1 cM should be 1 Mbp. Thus, the most likely underlying,
hidden, real states of AI are calculated for each SNP ac-
cording to Vitervi’s method, by which AI-positive regions
are defined by contiguous SNPs with “present” AI calls
flanked by either chromosomal end or an “absent” AI call.
Next, to determine the LOH status for each AI-positive
region (G), AsCN states at each SNP locus within G are
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inferred as “reduced ( )” and “not reduced ( )” for the¯R R
smaller AsCNs, and “increased ( )” and “not increased ( )”¯I I
for the larger AsCNs, using similar HMMs from the “ob-
served CN states” of the smaller and the larger AsCNs,
which are expressed as dichotomous values according to
thresholds and , respectively. The emission probabil-m mS L
ities of these models are
K K
˜ ˜P[min(log R , log R ) ! m FSi R]p 1 b2 A,i 2 B,i S S
K K
˜ ˜P[min(log R , log R ) m FSi R]p b2 A,i 2 B,i S S
K K
˜ ˜ ¯P[min(log R , log R ) ! m FSi R]p a2 A,i 2 B,i S S
K K
˜ ˜ ¯P[min(log R , log R ) m FSi R]p 1a2 A,i 2 B,i S S
and
K K
˜ ˜P[max(log R , log R ) 1 m FSi I]p 1 b2 A,i 2 B,i L L
K K
˜ ˜P[max(log R , log R ) m FSi I]p b2 A,i 2 B,i L L
K K
˜ ˜ ¯P[max(log R , log R ) 1 m FSi I]p a2 A,i 2 B,i L L
K K
˜ ˜ ¯P[max(log R , log R ) m FSi I]p 1a .2 A,i 2 B,i L L
These parameters ( , , , , , and ) are deter-m a b m a bS S S L L L
mined by evaluating sensitivities and specificities of the
results for 10%, 20%, and 30% tumor samples, where sen-
sitivities and specificities are calculated the same way as
was AI. Sensitivity and specificity are relatively stable for
between 0.03 and 0.13 and are relatively stable formS
between 0.04 and 0.09 in 20% and 30% tumor samplesmL
(fig. E1). We employed , , ,m p0.1 a p 0.3 b p 0.26S S S
, , and on the basis of the datam p 0.08 a p 0.27 b p 0.31L L L
for 20% tumor content.
Web Resources
The URLs for data presented herein are as follows:
ATCC, http://www.atcc.org/common/cultures/NavByApp.cfm
BACPAC Resources Center, http://bacpac.chori.org/
CNAG, http://www.genome.umin.jp/
dChip, http://www.dchip.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for JAK2, AML, PV, ET, and IMF)
PLASQ, http://genome.dfci.harvard.edu/˜tlaframb/PLASQ/
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